Churchill's Illustrated Medical Dictionary. New York, Churchill
Livingstone, 1989.
Stedman's Medical Dictionary, 26th ed. Baltimore, Williams
& Wilkins, 1995.
Proceedings of the International Workshop on Epidemiology,
Diagnosis and Management of Hepatitis C Infection. Medicine and the Community,
1996, 6-7:1-32.
Cite des Sciences et de l'Industrie--La Villette--Paris.
Conférence de consensus Traitement de l'hépatite C. Paris, 16-17
January. Cite des Sciences et de l'Industrie--La Villette--Paris. Ann Chir,
1997:212-216.
EASL International Consensus Conference on Hepatitis C.
Consensus Statement. Journal of Hepatology, 1999, 31:3-8.
Abrignani S, Houghton M, Hsu HH. Perspectives for a vaccine
against hepatitis C virus. Journal of Hepatology, 1999, 31:259-263.
Adinolfi L et al. Steatosis accelerates the progression
of liver damage of chronic hepatitis C patients and correlates with specific
HCV genotype and visceral obesity. Hepatology, 2001, 33:1358-1364.
Alberti A et al. Therapy of acute hepatitis C. Hepatology,
2003, 36:S195-S200.
Alter MJ. Epidemiology of hepatitis C. Hepatology, 1997,
26:62S-65S.
Alter MJ. Hepatitis C virus infection in the United States.
Journal of Hepatology, 1999, 31:88-91.
Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus
infection in thalassemia and haemodialysis patients in north Iran-Rasht. Journal
of Viral Hepatology, 2002, 9:390-392.
Barnes E et al. Long-term efficacy of treatment of chronic
hepatitis C with alpha interferon or alpha interferon and ribavirin. Journal
of Hepatology, 1999, 31:244-249.
Bonino F et al. Impact of interferon-alpha therapy on the
development of hepatocellular carcinoma in patients with liver cirrhosis:
results of an international survey. Journal of Viral Hepatology, 1997, 4:79-82.
Bukh J et al. High prevalence of hepatitis C virus (HCV)
RNA in dialysis patients: failure of commercially available antibody tests
to identify a significant number of patients with HCV infection. Copenhagen
Dialysis HCV Study Group. J Infect Dis, 1993, 168:1343-1348.
Buti M, Estaban R. Retreatment of interferon relapse patients
with chronic hepatitis C. Journal of Hepatology, 1999, 31:174-177.
Centers for Disease Control and Prevention. Hepatitis C
virus and disease, 1999.
Chang KM. Immunopathogenesis of hepatitis C virus infection.
Clinical Liver Disease, 2003, 7:89-105.
Choo Q-L et al. Isolation of a cDNA clone derived from
a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244:359-364.
Civeira M-P, Prieto J. Early predictors of response to
treatment in patients with chronic hepatitis C. Journal of Hepatology, 1999,
31:237-243.
Colombo M. Natural history and pathogenesis of hepatitis
C virus related hepatocellular carcinoma. Journal of Hepatology, 1999, 31:25-30.
Colombo M, Sangiovanni A. The European approach to hepatocellular
carcinoma. Hepatogastroenterology, 2002, 49:12-16.
De Francesco R. Molecular virology of the hepatitis C virus.
Journal of Hepatology, 1999, 31:47-53.
Degos F. Hepatitis C and alcohol. Journal of Hepatology,
1999, 31:113-118.
Dienes HP, Drebber U, von Both I. Liver biopsy in hepatitis
C. Journal of Hepatology, 1999, 31:43-46.
Dore G. HIV and hepatitis C coinfection. Proceedings of
10th Australasian Society for HIV Medicine Conference. 1998,
Fan ST, Cheung ST, Lo CM. Indications for liver transplantation
in patients with chronic hepatitis B and C virus infection and hepatocellular
carcinoma. J Gastroenterol Hepatol, 2000, 15:181-186.
Fang CT et al. Fluctuation of HCV viral load before seroconversion
in a healthy volunteer blood donor. Transfusion, 2003, 43:541-544.
Ferrari C et al. Immunopathogenesis of hepatitis C virus
infection. Journal of Hepatology, 1999, 31:31-38.
Foy E et al. Regulation of interferon regulatory factor-3
by the hepatitis C virus serine protease. Science, 2003, 300:1145-1148.
Fried MW, Hoofnagle JH. Therapy of hepatitis C. Seminars
in Liver Disease, 1995, 15:82-91.
Frilling A, Malago M, Broelsch CE. Current status of liver
transplantation for treatment of hepatocellular carcinoma. Dig Dis, 2001,
19:333-337.
Fujimura Y et al. Genotypes and multiple infections with
hepatitis C virus in patients with haemophilia A in Japan. Journal of Viral
Hepatology, 1996, 3:79-84.
Gerlach JT et al. Acute hepatitis C: high rate of both
spontaneous and treatment-induced viral clearance. Gastroenterology, 2003,
125:80-88.
Harris DR, Gonin R, Alter HJ. The relationship of acute
transfusion-associated hepatitis to the development of cirrhosis in the presence
of alcohol abuse. Ann Intern Med, 2001, 134:124.
Herrera JL. Iron depletion is not effective in inducing
a virologic response in patients with chronic hepatitis C who failed to respond
to interferon therapy. American Journal of Gastroenterology, 1999, 94:3571-3575.
Hickman IJ, Clouston AD, Macdonald GA. Effect of weight
reduction on liver histology and biochemistry in patients with chronic hepatitis
C. Gut, 2002, 51:89-94.
Hoofnagle JH. Management of hepatitis C: current and future
perspectives. Journal of Hepatology, 1999, 31:264-268.
Hourigan L, Macdonald G, Purdie D. Fibrosis in chronic
hepatitis C correlates significantly with body mass index and steatosis. Hepatology,
1999, 29:1215-1219.
Hsu HH, Greenberg HB. Hepatitis C. In: Hoeprich PD, Jordan
MC, Ronald AR, eds. Infectious Diseases. A treatise of infectious processes.,
5th ed. JB Lippincott Co, Philadelphia, 1994:820-825.
Huraib S et al. High prevalence of and risk factors for
hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis
strategies. Nephrol Dial Transplant, 1995, 10:470-474.
Jaeckel E et al. Treatment of acute hepatitis C with interferon
alfa-2b. New England Journal of Medicine, 2001, 345:1452-1457.
Jubin R et al. Amantadine and rimantadine have no direct
inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase,
and internal ribosomal entry site-mediated translation. Journal of Infectious
Diseases, 2000, 181:331-334.
Kane A et al. Transmission of hepatitis B, hepatitis C
and human immunodeficiency viruses through unsafe injections in the developing
world: model-based regional estimates. Bull World Health Organ, 1999, 77:801-807.
Kim WR. The burden of hepatitis C in the United States.
Hepatology, 2002, 36:S30-S34.
Klenerman P et al. Immunity to hepatitis C virus: stunned
but not defeated. Microbes Infect, 2002, 4:57-65.
Kuo G et al. An assay for circulating antibodies to a major
etiologic virus of human non-A, non-B hepatitis. Science, 1989, 244:362-364.
Lavanchy D, McMahon B. Worldwide prevalence and prevention
of hepatitis C. In: Liang TJ, Hoofnagle JH, eds. Hepatitis C. San Diego, Academic
Press, 2000:185-202.
Lavezzo B, Rizzetto M. Treatment of recurrent hepatitis
C virus infection after liver transplantation. Journal of Hepatology, 1999,
31:222-226.
Lee SR et al. Efficacy of a hepatitis C virus core antigen
enzyme-linked immunosorbent assay for the identification of 'window-phase'
blood donations. Vox Sanguinis, 2001, 80:19-23.
Lemon SM, Brown EA. Hepatitis C virus. In: Mandell GL,
Bennett JE, Dolin R, eds. Principle and Practice of Infectious Disease, Fourth.
New York, Churchill Livingstone, 1995:1474-1486.
Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations
in hepatitis C virus infection. Journal of Hepatology, 1999, 31:39-42.
Mansour-Ghanaei F et al. Prevalence of hepatitis B and
C seromarkers and abnormal liver function tests among hemophiliacs in Guilan
(northern province of Iran). Med Sci Monit, 2002, 8:CR797-800.
Marcellin P. Hepatitis C: the clinical spectrum of the
disease. Journal of Hepatology, 1999, 31:9-16.
Mast EE, Alter MJ, Margolis HS. Strategies to prevent and
control hepatitis B and C virus infections: a global perspective. Vaccine,
1999, 17:1730-1733.
Memon MI, Memon MA. Hepatitis C: an epidemiological review.
Journal of Viral Hepatology, 2002, 9:84-100.
Mondelli MU, Silini E. Clinical significance of hepatitis
C virus genotypes. Journal of Hepatology, 1999, 31:65-70.
Morikawa T et al. Prevalence and characterization of hepatitis
C virus in hemodialysis patients. Intern Med, 1999, 38:626-631.
Morin T, Pariente A. Hepatites aigues C: etude retrospective
de 62 cas. Gastroenterol Clin Biol, 2002, 26:994-1000.
Moya A et al. Hepatocellular carcinoma: Can it be considered
a controversial indication for liver transplantation in centers with high
rates of hepatitis C? Liver Transpl, 2002, 8:1020-1027.
Muerhoff AS et al. Detection of HCV core antigen in human
serum and plasma with an automated chemiluminescent immunoassay. Transfusion,
2002, 42:349-356.
Nakamoto Y et al. Analysis of the CD8-positive T cell response
in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers.
Journal of Medical Virology, 2003, 70:51-61.
Nascimbeni M et al. Kinetics of CD4+ and CD8+ memory T-cell
responses during hepatitis C virus rechallenge of previously recovered chimpanzees.
Journal of Virology, 2003, 77:4781-4793.
National Institutes of Health. Consensus Development Conference
Statement: Management of Hepatitis C: 2002, June 10-12. 2002,
Nomiyama K et al. Prevalence of hepatitis C virus antibody
in patients on chronic hemodialysis. Fukuoka Igaku Zasshi, 1998, 89:232-237.
Nubling CM et al. Sensitivity of HCV core antigen and HCV
RNA detection in the early infection phase. Transfusion, 2002, 42:1037-1045.
Ohno T, Lau JYN. The "gold-standard," accuracy,
the current concepts:hepatitis C virus genotypes and viremia. Hepatology,
1996, 24:1312-1315.
Pawlotsky J-M. Diagnostic tests for hepatitis C. Journal
of Hepatology, 1999, 31:71-79.
Powell EEHow host and viral factors affect fibrosis progression
in HCV. 3rd Australasian Conference on Hepatitis C.Melbourne2002
Poynard T et al. Effects of interferon therapy in "non
responder"patients with chronic hepatitis C. Journal of Hepatology, 1999,
31:178-183.
Poynard T et al. Interferon for acute hepatitis C. 2002,
Cochrane Database Syst Rev CD000369
Prince AM, Shata MT. Immunoprophylaxis of hepatitis C virus
infection. Clinical Liver Disease, 2001, 5:1091-1103.
Purcell RH. Hepatitis C virus. In: Webster RG, Granoff
A, eds. Encyclopedia of Virology. London, Academic Press Ltd, 1994:569-574.
Roayaie S et al. Comparison of surgical outcomes for hepatocellular
carcinoma in patients with hepatitis B versus hepatitis C: a western experience.
Ann Surg Oncol, 2000, 7:764-770.
Roy K et al. Monitoring hepatitis C virus infection among
injecting drug users in the European Union: a review of the literature. Epidemiol
Infect, 2002, 129:585.
Ruiz-Moreno M, Leal-Orozco A, Millàn A. Hepatitis
C virus infection in children. Journal of Hepatology, 1999, 31:124-129.
Saldanha J, Lelie N, Heath A. Establishment of the First
International Standard for Nucleic Acid Amplification Technology (NAT) Assays
for HCV RNA. Vox Sanguinis, 1998, 76:149-158.
Samuel D, Feray C. Recurrence of hepatitis C virus infection
after liver transplantation. Journal of Hepatology, 1999, 31:217-221.
Sanchez-Quijano A, Andreu J, Gavilan F. Influence of human
immunodeficiency virus type 1 infection on the natural course of chronic parenterally
acquired hepatitis C. Eur J Clin Microbiol Infect Dis, 1995, 14:949-953.
Saxena AK et al. Impact of dedicated space, dialysis equipment,
and nursing staff on the transmission of hepatitis C virus in a hemodialysis
unit of the middle east. Am J Infect Control, 31: 26-33. Am J Infect Control,
2003, 31:26-33.
Schalm SW et al. New treatment strategies in non-responder
patients with chronic hepatitis C. Journal of Hepatology, 1999, 31:184-188.
Schneeberger PM et al. The prevalence and incidence of
hepatitis C virus infections among dialysis patients in the Netherlands: a
nationwide prospective study. J Infect Dis, 2000, 182:1291-1299.
Schreiber GB et al. The risk of transfusion-transmitted
viral infections. New England Journal of Medicine, 1996, 334:1685-1690.
Schulman S, Grillner L. Antibodies against hepatitis C
in a population of Swedish haemophiliacs and heterosexual partners. Scandinavian
Journal of Infectious Diseases, 1990, 22:393-397.
Schuttler CG et al. Hepatitis C virus transmission by a
blood donation negative in nucleic acid amplification tests for viral RNA.
Lancet, 2000, 355:41-42.
Schvarcz R et al. Nosocomial transmission of hepatitis
C virus. Infection, 1997, 25:74-77.
Shata MT et al. Characterization of the immune response
against hepatitis C infection in recovered, and chronically infected chimpanzees.
Journal of Viral Hepatology, 2002, 9:400-410.
Simmonds P. Viral heterogeneity of the hepatitis C virus.
Journal of Hepatology, 1999, 31:54-60.
Tassopoulos NC. Treatment of patients with chronic hepatitis
C and normal ALT levels. Journal of Hepatology, 1999, 31:193-196.
Thomson M et al. The clearance of hepatitis C virus infection
in chimpanzees may not necessarily correlate with the appearance of acquired
immunity. Journal of Virology, 2003, 77:862-870.
Tosti ME et al. An estimate of the current risk of transmitting
blood-borne infections through blood transfusion in Italy. British Journal
of Haematology, 2002, 117:215-219.
Urdea MS et al. Hepatitis C - diagnosis and monitoring.
Clinical Chemistry, 1997, 43:1507-1511.
US Department of Health and Human Services.Centers for
Disease Control and Prevention. Recommendations for Prevention and Control
of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. Morbidity
and Mortality Weekly Report, 1998, 47.
van der Poel CL. Hepatitis C virus and blood transfusion:
past and present risks. Journal of Hepatology, 1999, 31:101-106.
Viral Hepatitis Prevention Board. Hepatitis A, B &
C: defining workers at risk. Viral Hepatitis, 1995, 3.
Walker CM. Hepatitis C virus. In: Ahmed R, Chen I, eds.
Persistent Viral Infections. Chichester, Wiley, 1999:93-115.
Wejstål R. Sexual transmission of hepatitis C virus.
Journal of Hepatology, 1999, 31:92-95.
Wiley TE et al. Impact of alcohol on the histological and
clinical progression of hepatitis C infection. Hepatology, 1998, 28:805-809.
World Health Organization. Hepatitis C. Weekly Epidemiological
Record, 1997, 72:65-69.
World Health Organization. Hepatitis C, 1997, http://www.who.int/inf-fs/en/fact164.html,
World Health Organization, http://www.who.int/inf-fs/en/fact164.html.
World Health Organization. Hepatitis C - global prevalence.
Weekly Epidemiological Record, 1997, 72:341-344.
World Health Organization. Global surveillance and control
of hepatitis C. Report of a WHO Consultation organized in Collaboration with
the Viral Hepatitis Prevention Board, Antwerp, Belgium. Journal of Viral Hepatology,
1999, 6:35-47.
World Health Organization. Hepatitis C - global prevalence
(update). Weekly Epidemiological Record, 1999, 74:425-427.
Yee TT et al. The natural history of HCV in a cohort of
haemophilic patients infected between 1961 and 1985. Gut, 2000, 47:851.
Zanetti AR, Tanzi E, Newell ML. Mother-to-infant transmission
of hepatitis C virus. Journal of Hepatology, 1999, 31:96-100.